Possible parathyroid calcium‐sensing set point shift in patients undergoing maintenance hemodialysis
Therapeutic Apheresis and Dialysis · 2023
DOI: 10.1111/1744-9987.13982 ↗Kurz gefasst
Leserbrief in der Zeitschrift Therapeutic Apheresis and Dialysis, 2023. Verfasst von Masayuki Tanemoto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, International University of Health and Welfare School of Medicine, Shizuoka, Japan. Hauptthemen laut MEDLINE: Calcium, Hyperparathyroidism, Secondary. Die Arbeit nennt 4 Literaturangaben. Gefördert von: Kyowa-Kirin.
Abstract (Originalsprache)
In chronic kidney disease–mineral and bone disorder (CKD–MBD), monitoring blood biochemical parameters is recommended, and albumin-corrected total serum calcium concentration (cCa) is generally used as a parameter of blood calcium [1]. However, several factors in the blood make cCa unreliable to indicate the physiological activity of blood calcium. We found six maintenance hemodialysis (MHD) patients who had hypocalcemia of cCa 5.5 mg/dL, hyperphosphatemia is an iPTH-elevating factor and would not have influenced the finding of iPTH not over the recommended range in them [3]. Thus, the finding suggests that some HD patients have iPTH not over the recommended range under hypocalcemia. The iPTH not over the recommended range under hypocalcemia would be resulted from a shift of the serum-calcium-sensing set point to a hypocalcemic state in their parathyroid. Since MHD patients with chronic hypocalcemia will have a steeper iCa increase during each dialysis session compared with those without it, chronic hypercalcemia under MHD might have induced the shift [4]. While hypocalcemia increased relative risk of mortality in MHD patients, hyperphosphatemia and hyperparathyroidism but not hypocalcemia could have increased the risk in them [3]. The absence of significant correlations of cCa and iCa with iPTH suggests that neither of them is a suitable parameter of CKD–MBD treatment for MHD patients who might have the serum-calcium-sensing set point shift. For the patients with the set point shift to a hypocalcemic state, treatment against hypocalcemia may not be necessary. Masayuki Tanemoto has received a grant awarded to his institute from Kyowa-Kirin. The authors declare no conflicts of interest.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, International University of Health and Welfare School of Medicine, Shizuoka, Japan.
ORCID-Profile: Masayuki Tanemoto
Förderung
- Kyowa-Kirin
Zitieren
APA
Tanemoto, M., Kasai, T., & Iida, Y. (2023). Possible parathyroid calcium‐sensing set point shift in patients undergoing maintenance hemodialysis. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.13982
Vancouver
Tanemoto M, Kasai T, Iida Y. Possible parathyroid calcium‐sensing set point shift in patients undergoing maintenance hemodialysis. Therapeutic Apheresis and Dialysis. 2023. doi:10.1111/1744-9987.13982
BibTeX
@article{Tanemoto2023,
author = {Tanemoto, Masayuki and Kasai, Takahiro and Iida, Yoshito},
title = {Possible parathyroid calcium‐sensing set point shift in patients undergoing maintenance hemodialysis},
journal = {Therapeutic Apheresis and Dialysis},
year = {2023},
doi = {10.1111/1744-9987.13982}
}
EUVIMED